Eremina Vera, Baelde Hans J, Quaggin Susan E
The Samuel Lunenfeld Research Institute, University of Toronto, Toronto, ON, Canada.
Nephron Physiol. 2007;106(2):p32-7. doi: 10.1159/000101798. Epub 2007 Jun 6.
BACKGROUND/AIMS: Vascular endothelial growth factor is a major regulator of angiogenesis and vascular permeability [Carmeliet et al.: Nature 1996;380:435-439]. The podocyte, the outermost layer of the glomerular filtration barrier, produces large amounts of VEGF-A. The observation that levels of VEGF-A are altered in glomerular diseases, the identification of a link between pre-eclampsia and elevated levels of a circulating soluble VEGF receptor, and the entry of anti-VEGF therapies into the clinical arena have generated intense interest in the functional role of VEGF-A in the glomerulus.
A variety of studies have been performed to address the role of VEGF-A signaling in the glomerulus. These include descriptions of expression patterns in human renal biopsies, cell culture studies to dissect paracrine versus autocrine signaling roles, and manipulation of VEGF-A expression in animal models using pharmacologic, biologic or genetic approaches.
Exquisite dosage sensitivity to VEGF-A exists in the developing glomerulus as small reductions in the expression of VEGF-A lead to profound changes in glomerular structure and function in mice. The use of VEGF inhibitors is associated with damage to the glomerular endothelium in animal models and proteinuria in patients, suggesting that local VEGF-A production is also required for maintenance of this specialized vascular bed.
Tight regulation of VEGF-A signaling is required for development and maintenance of the glomerular filtration barrier (GFB) and emphasizes the role of podocyte-endothelial crosstalk in the glomerulus. The relative contributions of various VEGF-A isoforms, the role of autocrine signaling in vivo and identification of factors and mechanisms that regulate constitutive expression, storage and delivery of VEGF-A in the glomerulus are still under investigation.
背景/目的:血管内皮生长因子是血管生成和血管通透性的主要调节因子[卡默利特等人:《自然》,1996年;380:435 - 439]。足细胞是肾小球滤过屏障的最外层,可产生大量的VEGF - A。肾小球疾病中VEGF - A水平发生改变,子痫前期与循环中可溶性VEGF受体水平升高之间存在联系,以及抗VEGF治疗进入临床领域,这些现象引发了人们对VEGF - A在肾小球中功能作用的浓厚兴趣。
已经进行了各种研究来探讨VEGF - A信号在肾小球中的作用。这些研究包括对人类肾活检中表达模式的描述、用于剖析旁分泌与自分泌信号作用的细胞培养研究,以及使用药理学、生物学或遗传学方法在动物模型中操纵VEGF - A的表达。
在发育中的肾小球中,对VEGF - A存在精确的剂量敏感性,因为VEGF - A表达的微小降低会导致小鼠肾小球结构和功能发生深刻变化。在动物模型中,使用VEGF抑制剂会导致肾小球内皮损伤,在患者中会导致蛋白尿,这表明维持这一特殊血管床也需要局部产生VEGF - A。
肾小球滤过屏障(GFB)的发育和维持需要对VEGF - A信号进行严格调控,并强调了足细胞 - 内皮细胞相互作用在肾小球中的作用。各种VEGF - A异构体的相对贡献、自分泌信号在体内的作用以及调节肾小球中VEGF - A组成性表达、储存和释放的因素及机制仍在研究中。